Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
Clinical trial NCT07089199 · RECRUITING
Trial details
- NCT number
- NCT07089199
- Sponsor
- Qilu Hospital of Shandong University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-25
- Primary completion
- 2026-07-10
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.